We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.49B
AUM Growth
+$287M
Cap. Flow
+$532M
Cap. Flow %
11.84%
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$173M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$75.9M
3
NVAX icon
Novavax
NVAX
+$49.8M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$43.3M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.5M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$71.6M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$51.4M
3
IMVT icon
Immunovant
IMVT
+$32.3M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$30.6M
5
KURA icon
Kura Oncology
KURA
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 75%
2 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXNX
26
DELISTED
Axonics, Inc. Common Stock
AXNX
$41.5M 0.92%
693,000
– –
DMTK
27
DELISTED
DermTech, Inc. Common Stock
DMTK
$40.6M 0.91%
+800,000
New +$41.8M
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$39.9M 0.89%
400,000
-100,000
-20% -$11.7M
IGMS
29
DELISTED
IGM Biosciences
IGMS
$38M 0.85%
495,769
-104,231
-17% -$9.49M
XLRN
30
DELISTED
Acceleron Pharma
XLRN
$37.3M 0.83%
275,000
-150,000
-35% -$19.4M
YMAB
31
DELISTED
Y-mAbs Therapeutics
YMAB
$37.2M 0.83%
1,230,000
-431,647
-26% -$17.7M
LBPH
32
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$37.2M 0.83%
+2,356,000
New +$38.5M
RXDX
33
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$36.6M 0.82%
+2,098,024
New +$43.3M
PRAX icon
34
Praxis Precision Medicines
PRAX
$10.1B
$35.2M 0.78%
71,610
– –
VERU icon
35
Veru
VERU
$37.4M
$32.3M 0.72%
+300,000
New +$37.8M
ALGS icon
36
Aligos Therapeutics
ALGS
$34.6M
$28.8M 0.64%
50,687
– –
MASS icon
37
908 Devices
MASS
$364M
$25.9M 0.58%
545,322
– –
NTLA icon
38
PUT
Intellia Therapeutics
NTLA
$1.67B
$24.1M 0.54%
300,000
– –
PLRX icon
39
Pliant Therapeutics
PLRX
$65M
$24M 0.54%
611,409
– –
BPMC
40
DELISTED
Blueprint Medicines
BPMC
$24M 0.54%
247,200
+22,200
+10% +$2.22M
APTO
41
DELISTED
Aptose Biosciences, Inc.
APTO
$23.9M 0.53%
+8,889
New +$17.6M
PHVS icon
42
Pharvaris
PHVS
$2.44B
$23.8M 0.53%
+864,143
New +$27.2M
TWST icon
43
Twist Bioscience
TWST
$7.25B
$22.9M 0.51%
185,000
-40,000
-18% -$6.07M
SRNE
44
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$22.7M 0.51%
2,750,000
-1,750,000
-39% -$18.5M
MORF
45
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$22.1M 0.49%
350,000
+150,000
+75% +$6.89M
SPRY icon
46
ARS Pharmaceuticals
SPRY
$612M
$21.8M 0.49%
500,000
– –
AKRO
47
DELISTED
Akero Therapeutics
AKRO
$21.5M 0.48%
742,549
– –
CABA icon
48
Cabaletta Bio
CABA
$455M
$21.1M 0.47%
1,904,424
– –
AGEN
49
Agenus
AGEN
$290M
$21.1M 0.47%
394,862
+38,212
+11% +$2.76M
MYOV
50
DELISTED
Myovant Sciences Ltd.
MYOV
$20.6M 0.46%
1,000,000
-700,000
-41% -$15.9M
1
2
3 4 5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Cormorant Asset Management deployed $532M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.

  • Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
  • Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
  • Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
  • Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
  • Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
  • Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
  • Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.